Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Chemotherapy-induced Thrombocytopenia in Relapsed Ovarian Cancer
NCT03622931Phase 2Terminated
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie
- Start
- Feb 2014
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie. Started Feb 2014; status: terminated.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT03622931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622931.